Showing 25 to 36 of 152 results
Grifols Stock Soars After Rejecting Brookfield Takeover Bid
Grifols' stock price jumped 8.99% to €13.51 after announcing its return to dividend payments and improved 2025 cash flow guidance, exceeding Brookfield's rejected €6.45 billion takeover bid from November 2024 by €1.85 billion in market capitalization.
Grifols Stock Soars After Rejecting Brookfield Takeover Bid
Grifols' stock price jumped 8.99% to €13.51 after announcing its return to dividend payments and improved 2025 cash flow guidance, exceeding Brookfield's rejected €6.45 billion takeover bid from November 2024 by €1.85 billion in market capitalization.
Progress
40% Bias Score
AstraZeneca's US Focus Raises Concerns About UK Commitment
AstraZeneca CEO Pascal Soriot's recent comments praising the US pharmaceutical market and his silence on a potential US stock market listing raise concerns about the company's commitment to the UK, highlighting funding disparities and potential relocation costs.
AstraZeneca's US Focus Raises Concerns About UK Commitment
AstraZeneca CEO Pascal Soriot's recent comments praising the US pharmaceutical market and his silence on a potential US stock market listing raise concerns about the company's commitment to the UK, highlighting funding disparities and potential relocation costs.
Progress
52% Bias Score
German Chemical Industry Reports Sharp Decline, Warns of Downward Spiral
The German chemical industry reported a 1% decrease in overall production in the first half of 2025, with chemical sales down 2% and production down 3%, while the pharmaceutical sector saw production rise 2% and sales 5%; the VCI president warned of an impending downward spiral due to order shortage...
German Chemical Industry Reports Sharp Decline, Warns of Downward Spiral
The German chemical industry reported a 1% decrease in overall production in the first half of 2025, with chemical sales down 2% and production down 3%, while the pharmaceutical sector saw production rise 2% and sales 5%; the VCI president warned of an impending downward spiral due to order shortage...
Progress
52% Bias Score
German Chemical Industry Stabilizes, but Recovery Remains Elusive
The German chemical and pharmaceutical industry's turnover slightly decreased by 0.5 percent to €107 billion in the first half of 2024, while production fell by 1 percent; however, the pharmaceutical sector showed a 2 percent production increase, counteracting the 3 percent decrease in the chemical ...
German Chemical Industry Stabilizes, but Recovery Remains Elusive
The German chemical and pharmaceutical industry's turnover slightly decreased by 0.5 percent to €107 billion in the first half of 2024, while production fell by 1 percent; however, the pharmaceutical sector showed a 2 percent production increase, counteracting the 3 percent decrease in the chemical ...
Progress
32% Bias Score
UK Government Faces Bank of England Opposition Over Pension Investment Mandate
The UK government seeks powers to mandate up to 10 percent of pension fund investments in specific sectors, prompting opposition from the Bank of England Governor Andrew Bailey who highlights concerns about the safety and caution required for pensioner investments.
UK Government Faces Bank of England Opposition Over Pension Investment Mandate
The UK government seeks powers to mandate up to 10 percent of pension fund investments in specific sectors, prompting opposition from the Bank of England Governor Andrew Bailey who highlights concerns about the safety and caution required for pensioner investments.
Progress
64% Bias Score
Medicaid Cuts to Cause Widespread Healthcare Disruption
The "Big Beautiful Bill" will cut \$1 trillion in Medicaid spending by 2034, potentially causing 15.9 million Americans to lose coverage and 477,000 healthcare jobs, while also impacting rural hospitals.
Medicaid Cuts to Cause Widespread Healthcare Disruption
The "Big Beautiful Bill" will cut \$1 trillion in Medicaid spending by 2034, potentially causing 15.9 million Americans to lose coverage and 477,000 healthcare jobs, while also impacting rural hospitals.
Progress
48% Bias Score
Novo Nordisk Shares Plunge on Lowered Profit Outlook Amidst Copycat Drug Competition
Novo Nordisk shares fell over 20% on Tuesday after the company announced a new CEO and lowered its profit expectations, citing weaker sales of its weight-loss drug Wegovy due to competition from copycat drugs; the company expects 8%-14% sales growth and 10%-16% operating profit growth for 2025.
Novo Nordisk Shares Plunge on Lowered Profit Outlook Amidst Copycat Drug Competition
Novo Nordisk shares fell over 20% on Tuesday after the company announced a new CEO and lowered its profit expectations, citing weaker sales of its weight-loss drug Wegovy due to competition from copycat drugs; the company expects 8%-14% sales growth and 10%-16% operating profit growth for 2025.
Progress
44% Bias Score
CVS Caremark's Weight-Loss Drug Switch Stirs Patient Outrage
CVS Caremark dropped Zepbound (tirzepatide) from its preferred drug list on July 1, 2025, replacing it with Wegovy (semaglutide) due to high costs, prompting negative patient reactions and concerns about treatment disruptions. A study showed Zepbound resulted in greater weight loss than Wegovy.
CVS Caremark's Weight-Loss Drug Switch Stirs Patient Outrage
CVS Caremark dropped Zepbound (tirzepatide) from its preferred drug list on July 1, 2025, replacing it with Wegovy (semaglutide) due to high costs, prompting negative patient reactions and concerns about treatment disruptions. A study showed Zepbound resulted in greater weight loss than Wegovy.
Progress
52% Bias Score
German Chemical Industry Stabilizes, but Full Recovery Remains Elusive
Germany's chemical and pharmaceutical industry experienced a slight decline in turnover (-0.5%) and production (-1%) in the first half of 2024, though the pharmaceutical sector showed growth; recovery is projected for 2025, dependent on political and economic factors.
German Chemical Industry Stabilizes, but Full Recovery Remains Elusive
Germany's chemical and pharmaceutical industry experienced a slight decline in turnover (-0.5%) and production (-1%) in the first half of 2024, though the pharmaceutical sector showed growth; recovery is projected for 2025, dependent on political and economic factors.
Progress
44% Bias Score
EU Economies Face Significant Losses from Potential US Tariffs
Germany and Ireland face the highest economic risks from potential US tariffs, with estimated GDP losses of 0.4% and 3% respectively, impacting the automotive and pharmaceutical sectors, while a 200% tariff on pharmaceuticals is considered unlikely but serves as leverage for US investment and lower ...
EU Economies Face Significant Losses from Potential US Tariffs
Germany and Ireland face the highest economic risks from potential US tariffs, with estimated GDP losses of 0.4% and 3% respectively, impacting the automotive and pharmaceutical sectors, while a 200% tariff on pharmaceuticals is considered unlikely but serves as leverage for US investment and lower ...
Progress
32% Bias Score
Texas Floods: Over 160 Missing After Deadly July 4th Weekend
Flash floods in Texas during the July 4th weekend killed over 100 people, with over 160 still missing, many of whom were unregistered in popular summer holiday camps and campgrounds, according to survivor accounts and official reports.
Texas Floods: Over 160 Missing After Deadly July 4th Weekend
Flash floods in Texas during the July 4th weekend killed over 100 people, with over 160 still missing, many of whom were unregistered in popular summer holiday camps and campgrounds, according to survivor accounts and official reports.
Progress
52% Bias Score
US-EU Tariff Dispute Threatens Ireland's Pharmaceutical Industry
Negotiations between the EU and the US over tariffs threaten Ireland's pharmaceutical industry, which employs 50,000 people and exports €100 billion annually. Failure to reach a deal by Wednesday could impose a 20% tariff, significantly harming Ireland's economy and potentially impacting US healthca...
US-EU Tariff Dispute Threatens Ireland's Pharmaceutical Industry
Negotiations between the EU and the US over tariffs threaten Ireland's pharmaceutical industry, which employs 50,000 people and exports €100 billion annually. Failure to reach a deal by Wednesday could impose a 20% tariff, significantly harming Ireland's economy and potentially impacting US healthca...
Progress
40% Bias Score
Showing 25 to 36 of 152 results